Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock

• Status: Unknown status
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Selection of tigecycline in severe sepsis and septic shock patients in empirical antibiotic therapy (Hai Zheng Energy Star ®) combined with piperacillin / tazobactam (tazocin ®) scheme, compared with the classical scheme, evaluate its efficacy, safety index.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital
• Collaborator: Zhejiang Hisun Pharmaceutical Co. Ltd.
• Treatments: Antifungal Agents; Miconazole; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Tigecycline

Criteria

Inclusion Criteria:

• Be consistent with severe sepsis and septic shock diagnosis standards

• Age above 18 years old, is expected in more than 5 days in ICU

• APACHEⅡ score>15

• By the patients themselves or their authorized person agreed to participate in the clinical trial and signed the informed consent

Exclusion Criteria:

• Allergic to penicillin, or of tigecycline allergic patients

• Patients with abnormal liver function is severe

• Be pregnant or lactating women

• Be not signed the informed consent of patients

• Any can be expected to increase patient risk or other factors can interfere with the results of a clinical trial